DOM-CR
DOM-CR, or DOM/CR, an acronym of "DOM-conformationally restrained", is a tetrahydroisoquinoline and cyclized phenethylamine related to the psychedelics DOM and 2C-D. It is a cyclized THIQ analogue of DOM and 2C-D.
DOM-CR shows more than 20-fold reduced affinity for the serotonin 5-HT2A receptor compared to DOM. In contrast to DOM, DOM-CR does not substitute for DOM in rodent drug discrimination tests, suggesting that it lacks psychedelic effects. Similarly, DOM-CR does not substitute for dextroamphetamine or MDMA, suggesting that it likewise lacks stimulant or entactogenic effects. However, DOM-CR does substitute for TDIQ, a selective α2-adrenergic receptor ligand. At high doses, DOM-CR produces behavioral disruption in drug discrimination tests. In contrast to DOM and amphetamine, DOM-CR does not produce hyperlocomotion in rodents.
DOM-CR was first described in the scientific literature by Richard Glennon and colleagues by 1996.
Analogues
Other cyclized THIQ analogues of psychoactive phenethylamines have also been developed and characterized. These include AMPH-CR, METH-CR, TDIQ, TDMIQ, N-methyl-DOM-CR, DOB-CR, and PMMA-CR. Conformational restriction of stimulant, hallucinogen, and/or entactogen phenethylamines into THIQ analogues, like the preceding compounds, usually reduces or abolishes their associated effects as well as their affinities for monoamine transporters and/or serotonin 5-HT2 receptors. However, it does not necessarily remove all pharmacological activity, as evidenced by some THIQs interacting with α2-adrenergic receptors as well as serotonin 5-HT1D, 5-HT6, and/or 5-HT7 receptors and producing behavioral effects in animals.Other cyclized analogues of DOM and related psychedelics include DOM-AT, DOM-AI, DMCPA, TFMBOX, jimscaline, TCB-2, LPH-5, and ZC-B.